Renaissance Technologies’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-159,950
| Closed | -$3.78M | – | 4194 |
|
|
2023
Q4 | $3.78M | Buy |
159,950
+46,500
| +41% | +$828K | 0.01% | 1529 |
|
|
2023
Q3 | $1.69M | Sell |
113,450
-156,570
| -58% | -$2.08M | ﹤0.01% | 1963 |
|
|
2023
Q2 | $2.96M | Sell |
270,020
-211,480
| -44% | -$1.97M | ﹤0.01% | 1748 |
|
|
2023
Q1 | $4.2M | Sell |
481,500
-24,400
| -5% | -$195K | 0.01% | 1577 |
|
|
2022
Q4 | $3.17M | Buy |
505,900
+15,100
| +3% | +$57.4K | ﹤0.01% | 1781 |
|
|
2022
Q3 | $1.72M | Sell |
490,800
-23,820
| -5% | -$85.6K | ﹤0.01% | 2115 |
|
|
2022
Q2 | $1.52M | Buy |
514,620
+55,085
| +12% | +$132K | ﹤0.01% | 2401 |
|
|
2022
Q1 | $1.43M | Buy |
459,535
+243,915
| +113% | +$768K | ﹤0.01% | 2476 |
|
|
2021
Q4 | $729K | Sell |
215,620
-296,971
| -58% | -$1.13M | ﹤0.01% | 2884 |
|
|
2021
Q3 | $1.87M | Sell |
512,591
-283,629
| -36% | -$1.12M | ﹤0.01% | 2142 |
|
|
2021
Q2 | $3.47M | Sell |
796,220
-93,943
| -11% | -$416K | ﹤0.01% | 1866 |
|
|
2021
Q1 | $4.04M | Buy |
890,163
+480,443
| +117% | +$2.59M | 0.01% | 1788 |
|
|
2020
Q4 | $2.35M | Buy |
409,720
+250,800
| +158% | +$1.9M | ﹤0.01% | 2023 |
|
|
2020
Q3 | $1.15M | Buy |
158,920
+70,400
| +80% | +$376K | ﹤0.01% | 2441 |
|
|
2020
Q2 | $309K | Buy |
+88,520
| New | +$255K | ﹤0.01% | 3032 |
|
|
2020
Q1 | – | Sell |
-424,840
| Closed | -$833K | – | 3905 |
|
|
2019
Q4 | $833K | Buy |
424,840
+384,920
| +964% | +$1.45M | ﹤0.01% | 2713 |
|
|
2019
Q3 | $204K | Buy |
+39,920
| New | +$242K | ﹤0.01% | 3138 |
|
|
2018
Q2 | – | Sell |
-134,500
| Closed | -$1.75M | – | 3604 |
|
|
2018
Q1 | $1.75M | Sell |
134,500
-59,600
| -31% | -$741K | ﹤0.01% | 2394 |
|
|
2017
Q4 | $1.79M | Sell |
194,100
-376,100
| -66% | -$3.21M | ﹤0.01% | 2409 |
|
|
2017
Q3 | $4.6M | Buy |
570,200
+256,808
| +82% | +$1.74M | 0.01% | 1827 |
|
|
2017
Q2 | $1.8M | Buy |
313,392
+81,443
| +35% | +$347K | ﹤0.01% | 2310 |
|
|
2017
Q1 | $997K | Buy |
231,949
+114,549
| +98% | +$329K | ﹤0.01% | 2544 |
|
|
2016
Q4 | $203K | Sell |
117,400
-3,400
| -3% | -$6K | ﹤0.01% | 3000 |
|
|
2016
Q3 | $234K | Sell |
120,800
-7,500
| -6% | -$14.9K | ﹤0.01% | 3028 |
|
|
2016
Q2 | $223K | Buy |
128,300
+17,300
| +16% | +$35.9K | ﹤0.01% | 3019 |
|
|
2016
Q1 | $150K | Buy |
111,000
+50,100
| +82% | +$62.1K | ﹤0.01% | 3153 |
|
|
2015
Q4 | $103K | Buy |
+60,900
| New | +$99.3K | ﹤0.01% | 3106 |
|
Other funds holding CBAY
Renaissance Technologies's CBAY Position: Q1 2024 in Review
Renaissance Technologies sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 159,950 shares — an estimated $3.78M sold.
Renaissance Technologies first reported a position in CBAY in Q4 2015 and held it in 27 quarters. The position peaked at $4.6M in Q3 2017. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Renaissance Technologies reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Renaissance Technologies sold 159,950 Cymabay Therapeutics shares in Q1 2024, an estimated $3.78M.
- Renaissance Technologies first reported a position in Cymabay Therapeutics in Q4 2015 and held it in 27 quarters.
- Renaissance Technologies's Cymabay Therapeutics position peaked at $4.6M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.